Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath Purged Non-myeloablative Stem Cell Transplantation
NCT00580034Phase 2Completed
- Start
- Feb 2003
- Primary completion
- Apr 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in lymphoma, multiple myeloma (MM), leukemia, myelodysplastic syndrome (MDS), solid tumor. Started Feb 2003; status: completed.
02
Drugs
alemtuzumab
03
Conditions
lymphomamultiple myeloma (MM)leukemiamyelodysplastic syndrome (MDS)solid tumor
Beyond the preview
Go deeper on NCT00580034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00580034.